PT  - JOURNAL ARTICLE
AU  - Butelman, Eduardo R.
AU  - Huang, Yuefeng
AU  - Cathomas, Flurin
AU  - Gaudreault, Pierre-Olivier
AU  - Roussos, Panos
AU  - Russo, Scott J.
AU  - Goldstein, Rita Z.
AU  - Alia-Klein, Nelly
TI  - Serum cytokine and inflammatory markers in individuals with heroin use disorder: potential biomarkers for diagnosis and disease severity
AID  - 10.1101/2024.04.29.24306559
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.29.24306559
4099  - http://medrxiv.org/content/early/2024/05/01/2024.04.29.24306559.short
4100  - http://medrxiv.org/content/early/2024/05/01/2024.04.29.24306559.full
AB  - Opioid use disorders cause major morbidity and mortality, and there is a pressing need for novel mechanistic targets and biomarkers for diagnosis and prognosis. Exposure to mu-opioid receptor (MOR) agonists causes changes in cytokine and inflammatory protein networks in peripheral blood, and also in brain glia and neurons. Individuals with heroin use disorder (iHUD) show dysregulated levels of several cytokines in blood. However, there is limited data on a comprehensive panel of such markers in iHUD versus healthy controls (HC), especially as a multi-target biomarker. We used a validated proximity extension assay for relative quantification of 92 cytokines and inflammatory proteins in serum of iHUD on medication assisted therapy (MAT; n=21), versus HC (n=24). Twenty-nine targets showed significant group differences (primarily iHUD>HC), surviving multiple comparison correction (p=0.05). This included 19 members of canonical cytokine families, including specific chemokines, interleukins, growth factors, and tumor necrosis factor (TNF)-related proteins. For dimensionality reduction, data from these 19 cytokines were entered into a principal component (PC) analysis, and PC1 scores were iHUD>HC (p<0.0001). A receiver-operating characteristic (ROC) curve analysis yielded an AUROC=91.7% (p<0.0001). This PC1 score remained a positive predictor of being in the HUD group in a multivariable logistic regression, which included demographic/clinical variables. Overall, this study shows a panel of cytokines that differ significantly between iHUD and HC, and provides a multi-target “cytokine biomarker score” for potential diagnostic purposes, and examination of disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding Statement: This work was supported by NIDA U01DA053625 (ERB), R01DA049547 (NAK), R01DA047880 (PR), NCCIH R01AT010627 (RZG), NIMH R01MH104559 (SJR), R01MH127820 (SJR), and NIA R01AG067025 (PR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Icahn School of Medicine at Mount Sinai gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced in the present study are available upon reasonable request to the authors, subject to IRB, consent and privacy issues.AUROCArea under the receiver-operating curveBMIBody mass indexFDRFalse discovery rateHGFHepatocyte growth factorHCHealthy controlsHUDHeroin use disorderiHUDIndividuals with heroin use disorderILinterleukinIQRInter-quartile rangeLODlimit of detectionMORMu-opioid receptorsNPXNormalized protein expression (relative quantification from Olink assay; log2 units)OSMOncostatin MPC1 scoresPrincipal component 1 scoresPCAPrincipal component analysisROCReceiver-operating curveSCFStem cell factorTNFTumor necrosis factor